Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease

NCT02579252 is registered in ClinicalTrials.gov with Axon Neuroscience SE as lead sponsor.

NCT NCT02579252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02579252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease
Lead sponsor
Axon Neuroscience SE
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2016
Completion date
June 30, 2019
Enrollment
208 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease